The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the biotech sector's resilience amid market shifts, Regeneron Pharmaceuticals reported Q2 2026 financial results that comfortably exceeded Street estimates. This strong performance was primarily driven by higher sales of the new high-dose version of its Eylea eye therapy, effectively reversing prior negative profit projections. The company achieved an 11% year-over-year growth in non-GAAP earnings per share.
Per market data, the strategic collaboration with Sanofi, specifically the profits from the drug Dupixent, contributed significantly to improved profit margins and increased overall revenues. This momentum comes as financial data shows stability in the company's operational performance, bolstering investor confidence in Regeneron's ability to maintain its growth trajectory despite broader sector challenges.
At the close on July 28, 2026, REGN was priced at $695.18, while the 0R2M.L ticker stood at $688.03. Looking ahead, traders are monitoring broader US economic indicators such as the Services PMI for general market sentiment, while the primary focus remains on the continued sales performance of the company's core therapies in upcoming quarters.